Helixmith Co

Helixmith Co Intangible Assets

The Intangible Assets of Helixmith Co (084990.KQ) as of Oct 21, 2026 is 99.45 M KRW.

Intangible Assets

99.45 MKRW

Last updated:

Intangible Assets of Helixmith Co is 2024 99.45 M KRW. Intangible Assets of Helixmith Co was 2023 0.00 KRW. It decreases by % higher compared to the previous year.

The Helixmith Co Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2017
46.21 B KRW
Jan 1, 2018
71.18 B KRW
Jan 1, 2019
2.05 B KRW
Jan 1, 2020
5.74 B KRW
Jan 1, 2021
7.94 B KRW
Jan 1, 2022
11.94 B KRW
Jan 1, 2023
0.00 KRW
Jan 1, 2024
99.45 M KRW
The Helixmith Co Intangible Assets history
YEARIntangible AssetsYoY
99.45 MKRW—
0.00KRW-100.00%
11.94 BKRW+50.38%
7.94 BKRW+38.30%
5.74 BKRW+180.60%
2.05 BKRW-97.13%
71.18 BKRW+54.04%
46.21 BKRW+141.93%
19.10 BKRW-64.46%
53.73 BKRW+14.33%
47.00 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Helixmith Co Stock analysis

What does Helixmith Co do? Helixmith Co., Ltd. generates revenue through its Natural Products Business segment, which develops and sells raw materials for functional materials and health functional foods under brands like Alex, Murphine, and Nimosin. The New Biopharmaceutical Business segment focuses on developing treatments for diabetic neuropathy, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis, ischemic heart disease, and anticancer therapies. Customers include companies in the health and pharmaceutical sectors seeking natural ingredients and specialized medical treatments. The company serves two distinct market segments: one for natural product raw materials and another for advanced biopharmaceutical solutions. The Natural Products Business segment targets clients requiring raw materials for functional materials and health functional foods, leveraging branded products Alex, Murphine, and Nimosin. The New Biopharmaceutical Business segment caters to healthcare providers and pharmaceutical firms developing treatments for specific medical conditions, including diabetic neuropathy, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis, ischemic heart disease, and anticancer applications. Both segments operate within the broader health and biotechnology industries, with the company's revenue streams derived from product sales across these specialized markets. Helixmith Co., Ltd. monetizes its research and development efforts through the commercialization of natural substance-based raw materials and biopharmaceutical treatments. The company's product portfolio includes Alex, Murphine, and Nimosin for the natural products market, while its biopharmaceutical segment offers treatments for diabetic neuropathy, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis, ischemic heart disease, and anticancer conditions. Revenue is generated from direct sales to businesses in the health, functional food, and pharmaceutical sectors, with no mention of additional revenue streams such as licensing or partnerships. Helixmith Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Helixmith Co stock

Intangible Assets of Helixmith Co is 99.45 M KRW in 2024.

On Eulerpool you can find the complete historical development of Intangible Assets Helixmith Co since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Helixmith Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Helixmith Co

All Key Metrics — Helixmith Co